Moderna shares fell as much as 10%.

BlockBeats news, October 23, according to BIT (bit.com) market data, Moderna's stock price fell as much as 10%, with a cumulative decline of 26% over two days.

Previously reported, the Phase III data for the personalized melanoma vaccine jointly developed by Moderna and Merck was leaked in advance; despite positive clinical results, the stock still suffered heavy selling.